Lets translate this into clinical reality Absolute risk reduction 3.7% over 3 years NNT 27 So yes this is clinically meaningful But heres the uncomfortable truth: This benefit is conditional
Providers say theyre within FDA guidelines for the use of compounded drugs because theyre creating custom doses to meet each patients specific medical needs.) The FDA says some semaglutide products sold as compounds might be the salt forms, which differ from the base forms used in approved drugs
It should be recognised that there is currently no universally accepted definition of chronic constipation
Getting back to the discussion, So Consider a few data points from the companies that reported this quarter to comprehend what I am trying to explain above: Zydus Lifesciences delivered consolidated revenues of 27,150 Cr for FY26, up 17% YoY, with an EBITDA margin of 31.2% which is the highest-ever operating margin in the companys history
Methylcobalamin in Peripheral Neuropathy Methylcobalamine is known to aid in the regeneration of nerves and alleviation of symptoms in cases such as diabetic neuropathy, where patients often report decreased numbness and tingling sensations along with pain relief
Not tested for safety and efficacy